J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):169-172. doi: 10.1016/j.japh.2022.08.002. Epub 2022 Aug 5.
Roughly 10% of the U.S. population has a documented penicillin (PCN) allergy. Among these individuals, over 95% are able to tolerate PCNs. The inability to use PCNs can result in suboptimal outcomes. In August 2019, Lawrence Memorial Hospital Health System implemented a pharmacist-led PCN allergy testing service to assist with delabeling PCN allergies and increase access to this class of antibiotics.
The primary objective was to describe the number of patients who underwent PCN allergy testing and were delabeled from PCN allergy. A secondary objective was to report the number of patients who received and tolerated PCN antibiotics after being delabeled from PCN allergy.
This retrospective chart review was conducted during the initial 17 months of a pharmacist-led PCN allergy testing service. Eligible patients with a history of an immunoglobulin E (IgE)-mediated reaction underwent a 3-step test that consisted of a scratch test, an intradermal test, and an oral challenge. Eligible patients who did not have a history of IgE-mediated reaction underwent a 2-step graded oral challenge. Descriptive statistics were used for data analysis.
Between August 2019 and January 2022, 70 patients underwent testing, and 66 patients were delabeled from PCN allergy. Four patients who underwent the 3-step test developed reactions of mild to moderate severity. All patients who underwent the graded oral challenge were delabeled from PCN allergy. The rate of PCN allergy was 5.7%, whereas the rate of type I IgE-mediated reaction was 1.4%. All 23 patients who received an antibiotic from the PCN class after a negative allergy test tolerated the PCN antibiotic without an incident.
PCN allergy testing is an effective way to delabel PCN allergies from most patients presenting with a PCN allergy history. Skin testing followed by an oral challenge or a graded oral challenge alone are safe methods for conducting PCN allergy testing in the primary care setting.
大约 10%的美国人口有记录的青霉素(PCN)过敏。在这些人中,超过 95%的人能够耐受 PCN。不能使用 PCN 会导致治疗效果不理想。2019 年 8 月,劳伦斯纪念医院卫生系统实施了一项由药剂师主导的 PCN 过敏测试服务,以协助消除 PCN 过敏,并增加此类抗生素的使用。
主要目的是描述接受 PCN 过敏测试并从 PCN 过敏中消除标签的患者数量。次要目的是报告从 PCN 过敏中消除标签后接受并耐受 PCN 抗生素的患者数量。
这是一项由药剂师主导的 PCN 过敏测试服务开始后的最初 17 个月进行的回顾性图表审查。有免疫球蛋白 E(IgE)介导反应史的合格患者进行了 3 步测试,包括划痕试验、皮内试验和口服挑战。没有 IgE 介导反应史的合格患者进行了 2 步分级口服挑战。使用描述性统计数据进行数据分析。
2019 年 8 月至 2022 年 1 月期间,70 名患者接受了测试,66 名患者从 PCN 过敏中消除了标签。4 名接受 3 步测试的患者出现了轻度至中度严重的反应。所有接受分级口服挑战的患者均从 PCN 过敏中消除了标签。PCN 过敏的发生率为 5.7%,而 I 型 IgE 介导反应的发生率为 1.4%。所有 23 名在阴性过敏测试后接受 PCN 类抗生素的患者均耐受了 PCN 抗生素,没有出现不良事件。
PCN 过敏测试是一种有效的方法,可以消除大多数有 PCN 过敏史的患者的 PCN 过敏。在初级保健环境中,皮肤测试后进行口服挑战或单独进行分级口服挑战是进行 PCN 过敏测试的安全方法。